JOURNAL OF PRACTICAL HEPATOLOGY ›› 2016, Vol. 19 ›› Issue (6): 749-752.doi: 10.3969/j.issn.1672-5069.2016.06.035
Previous Articles Next Articles
Zhu Tiantian,Li Jun,Zhu Chuanlong.
Received:
2016-05-30
Online:
2016-11-10
Published:
2016-11-28
Zhu Tiantian,Li Jun,Zhu Chuanlong.. Pattern recognition receptors in HBV infection[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(6): 749-752.
[1] Zhang X,Ma Z,Liu H,et al. Role of Toll-like receptor 2 in the immune response against hepadnaviral infection. J Hepatol,2012,57(3):522-528. [2] Ait-Goughoulte M,Lucifora J,Zoulim F,et al. Innate antiviral immune responses to hepatitis B virus. Viruses,2010,2(7):1394-1410. [3] Pei RJ,Chen XW,Lu MJ. Control of hepatitis B virus replication by interferons and Toll-like receptor signaling pathways. World J Gastroenterol,2014,20(33):11618-11629. [4] Broering R,Lu M,Schlaak J F. Role of Toll-like receptors in liver health and disease. Clin Sci(Lond),2011,121(10):415-426. [5] 李红霞,潘晨,陈立,等. Toll样受体与慢性乙型肝炎的研究进展. 国际流行病学传染病学杂志,2010,37(3):195-198. [6] Palumbo GA,Scisciani C,Pediconi N,et al. IL6 inhibits HBV transcription by targeting the epigenetic control of the nuclear cccDNA minichromosome. Plos One,2015,10(11):e0142599. [7] Akira S,Takeda K. Toll-like receptor signaling. Nat Rev Immunol,2004,4:499-511. [8] Takeda K,Kaisho T,Akira S. Toll-like receptors. Annu Rev Immunol,2003,21:335-376. [9] Akira S,Uematsu S,Takeuchi O. Pathogen recognition and innate immunity. Cell,2006,124(4):783-801. [10] Bertoletti A,Ferrari C. Innate and adaptive immune responses in chronic hepatitis B virus infections:towards restoration of immune control of viral infection. Commun Soil Sci Plan,2013, 61(12):438-444. [11] Guo H,Jiang D,Ma D,et al. Activation of pattern recognition receptor-mediated innate immunity inhibits the replication of hepatitis B virus in human hepatocyte-derived cells. J Virol,2009,83(2):847-858. [12] Seki E,Brenner DA.Toll-like receptors and adaptor molecules in liver disease:update. Hepatology,2008,48(1):322-335. [13] Hosel M,Quasdorff M,Wiegmann K,et al. Not interferon,but interleukin-6 controls early gene expression in hepatitis B virus infection. Hepatology,2009,50(6):1773-1782. [14] Zhang E,Lu M. Toll-like receptor(TLR)-mediated innate immune responses in the control of hepatitis B virus (HBV)infection. Med Microbiol Immun,2015,204(1):11-20. [15] Honda K,Taniguchi T. IRFs:master regulators of signalling by Toll-like receptors and cytosolic pattern-recognition receptors. Nat Rev Immunol,2006,6(9):644-658. [16] Wu J,Meng Z,Jiang M,et al. Hepatitis B virus suppresses toll-like receptor-mediated innate immune responses in murine parenchymal and nonparenchymal liver cells.Hepatology,2009,49(4):1132-1140. [17] Wu J,Meng Z,Jiang M,et al. Toll-like receptor-induced innate immune responses in non parenchymal liver cells are cell type-specific.Immunology,2009,129(3):363-374. [18] Shi B,Ren G,Hu Y,et al. HBsAg inhibits IFN-α production in plasmacytoid dendritic cells through TNF-α and IL-10 induction in monocytes. Plos One,2012,7(9):e44900. [19] Romagne F. Current and future drugs targeting one class of innate immunity receptors:the Toll-like receptors. Drug Discov,2007,12(1-2):80-87. [20] Loo YM,Gale M. Immune signaling by RIG-I-like receptors. Immunity,2011,34(5):680-692. [21] Wieland SF,Eustaquio A,Whittenbauer C,et al. Interferon prevents formation of replication-competent hepatitis B virus RNA-containing nucleocapsids. Pro Natl Acad Sci USA,2005,102(28):9913-9917. [22] Akira S,Uematsu S,Takeuchi O. Pathogen Recognition and Innate Immunity. Cell,2006,124(4):783-801. [23] Lee MS,Kim YJ. Signaling pathways downstream of pattern-recognition receptors and their cross talk. Annu Rev Biochem,2007,76(76):447-480. [24] Komai-Koma M,Jones L,Ogg GS,et al. TLR2 is expressed on activated T cells as a costimulatory receptor. Pro Natl Acad Sci USA,2004,101(9):3029-3034. [25] Mercier BC,Cottalorda A,Coupet CA,et al. TLR2 engagement on CD8 T cells enables generation of functional memory cells in response to a suboptimal TCR signal. J Immunol,2009,182(4):1860-1867. [26] Lanford RE,Guerra B,Chavez D,et al. GS-9620,an oral agonist of Toll-like receptor-7,induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees. Gastroenterology,2013,144(7):1508-1517. [27] Fosdick A,Zheng J,Pflanz S,et al. Pharmacokinetic and pharmacodynamic properties of GS-9620,a novel Toll-like receptor 7 agonist,demonstrate interferon-stimulated gene induction without detectable serum interferon at low oral doses. J Pharmacol Exp Ther,2014,348(1):96-105. [28] Jo J,Tan AT,Ussher JE,et al. Toll-like receptor 8 agonist and bacteria trigger potent activation of innate immune cells in human liver. Plos Pathog,2014,10(6):e1004210. [29] Sawhney R,Visvanathan K. Polymorphisms of toll-like receptors and their pathways in viral hepatitis. Antiv Ther,2011,16(4):443-458. [30] Xu N,Yao HP,Lyu GC,et al. Downregulation of TLR7/9 leads to deficient production of IFN-α from plasmacytoid dendritic cells in chronic hepatitis B. Inflamm Res,2012,61(9):997-1004. [31] Ning L,Qian L,Qian Z,et al. Impaired TLR3/IFN-β signaling in monocyte-derived dendritic cells from patients with acute-on-chronic hepatitis B liver failure:Relevance to the severity of liver damage. Biochem Biophys Res Commun,2009,390(3):630-635. [32] Vincent E,Zannetti C,Lucifora J,et al. Hepatitis B virus impairs TLR9 expression and function in plasmacytoid dendritic cells. PLoS One,2011,6(10):e26315. [33] Dienstag JL. Hepatitis B virus infection. N Engl J Med,2008,359(14):1486-1500. [34] Jiang M,Broering R,Trippler M,et al. Toll-like receptor-mediated immune responses are attenuated in the presence of high levels of hepatitis B virus surface antigen. J Viral Hepat,2014,21(12):860-872. [35] Wang S,Chen Z,Hu C,et al. Hepatitis B virus surface antigen selectively inhibits TLR2 ligand-induced IL-12 production in monocytes/macrophages by interfering with JNK activation. J Immunol,2013,190(10):5142-5151. [36] Visvanathan K,Skinner NA,Thompson AJ, et al. Regulation of Toll-like receptor-2 expression in chronic hepatitis B by the precore protein.Hepatology,2007,45(1):102-110. [37] Lang T,Lo C,Skinner N,et al. The hepatitis B e antigen (HBeAg) targets and suppresses activation of the Toll-like receptor signaling pathway. J Hepatol,2011,55(4):762-769. [38] Wu M,Xu Y,Lin S,et al. Hepatitis B virus polymerase inhibits the interferon-inducible MyD88 promoter by blocking nuclear translocation of Stat 1. J Gen Virol,2007,88(12):3260-3269. [39] Yu S,Chen J,Wu M,et al. Hepatitis B virus polymerase inhibits RIG-I-and Toll-like receptor 3-mediated beta interferon induction in human hepatocytes through interference with interferon regulatory factor 3 activation and dampening of the interaction between TBK1/IKKepsilon and D. J Gen Virol,2010,91(Pt 8):2080-2090. [40] Chen J,Wu M,Zhang X,et al. Hepatitis B virus polymerase impairs interferon-α-induced STA T activation through inhibition of importin-α5 and protein kinase C-δ. Hepatology,2013,57(2):470-482. [41] Zhang ZH,Wu CC,Chen XW,et al. Genetic variation of hepatitis B virus and its significance for pathogenesis. World J Gastroenterol,2016,22(1):126-144. [42] Protzer U,Maini MK,Knolle PA. Living in the liver: hepatic infections. Nat Rev Immunol,2012,12:201-213. [43] Al-Qahtani A,Al-Ahdal M,Abdo A,et al. Toll-like receptor 3 polymorphism and its association with hepatitis B virus infection in Saudi Arabian patients. J Med Virol,2012,84(9):1353-1359. [44] Shahrakyvahed A,Sanchooli J,Sanadgol N,et al. TLR9:an important molecule in the fight against hepatitis B virus. Postgrad Med J,2014,90(1065):396-401. [45] Liu HY,Zhang XY. Innate immune recognition of hepatitis B virus. World J Hepatol,2015,7(21):2319-2322. [46] Sato S,Li K,Kameyama T,et al. The RNA sensor RIG-I dually functions as an innate sensor and direct antiviral factor for hepatitis B virus. Immunity,2015,42(1):1-10. [47] Ebrahim M,Mirzaei V,Bidaki R,et al. Are RIG-1 and MDA5 expressions associated with chronic HBV infection. Viral Immunol,2015,28(9):504-508. [48] Lu HL,Liao F. Melanoma differentiation-associated gene 5 senses hepatitis B virus and activates innate immune signaling to suppress virus replication. J Immunol,2013,191(6):3264-3276. [49] Zhu C,Xiao F,Lin W. EFTUD2 on innate immunity. Oncotarget, 2015,6:32313-32314. |
[1] | ZhangLining, Liu Zhigang, GaoCaixia, et al.. Application of dietary intervention with authorized education in patients with hepatitis B virus associated glomerulonephritis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(5): 799-800. |
[2] | Wang Ping, Zhou Xiaojia, Liu Xinhua. Application of video-based health education in patients with hepatitis B virus associated glomerulonephritis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(3): 451-452. |
[3] | Weng Yerui, Fu Aizhen. Investigation of milk HBV DNA in pregnant women with chronic HBV infection [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(3): 457-458. |
[4] | Zhan Guoqing, Tan Huabing, Li Fang, et al. Effect of antiviral therapy with entecavir on HBV reactivation in serum HBV DNA negative hepatitis B virus infection-reduced patients with hepatocellular carcinoma receiving transcatheter arterial chemoemholization [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(1): 96-99. |
[5] | Ma Yong.. Prevalence of hepatitis B infection in infants with hepatitis B virus-carrying mothers [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(4): 486-487. |
[6] | Du Jinghua, Zhang Yu, Hao Yizhuo.. Serum hepatitis B virus large surface protein in patients with hepatitis B viral infection [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(5): 599-600. |
[7] | Su Minghua, Jiang Jianning. Hepatitis B virus genotype 6:Epidemiology and treatment of patients [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(4): 497-499. |
[8] | Wang Yi,Yang Zhenhua. Role of miRNAs in HBV infection and hepatocarcinogenesis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(3): 381-384. |
[9] | Huang Pengyu, Xu Dongping. Precore and core promoter mutations of hepatitis B virus and their roles in acute-on-chronic liver failure [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(2): 241-244. |
[10] | Lu Wei, Zhang Zhanqing, Shen Fang, Wang Yanbing, Ding Rongrong, Zhou Xinlan, Feng Yanling. Serum HBsAg levels and HBV DNA loads in prediction of hepatic histological activity grading and fibrosis staging in patients with chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(1): 20-24. |
[11] | Zhao Heping, Hou Tianqing, Ding Baohua, Zhang Ziran, Li jing, Liu Xiaolei, ShaoDandan, Guo Shimin. Efficacy of entecavir and immunotherapy in treatment of hepatitis B virus carriers [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(1): 25-28. |
[12] | Chen Xuefu, Chen Xiaoping, Ma Xiaojun, et al.. Liver pathologic changes in chronic Hepatitis B patients with mildly elevated serum alanine aminotransferase levels after two-year followed-up [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2015, 18(6): 594-597. |
[13] | Zhu Yunmeng,Feng Jiliang,Song Chenzhao,et al.. Expression of HBsAg and hepatocyte nuclear factor 4 alpha in HBV-associated hepatocellular carcinoma tissues [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2015, 18(5): 517-520. |
[14] | Huang Shunmei,Wang Junzhong,Song Zhitao,et al.. Impact of three immunosuppressors on HBV replication in HBV plasmid transfected mice [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2015, 18(4): 348-351. |
[15] | YE Xiaoling, LIU Yan, XU Dongping.. Research progress of drug-resistant mutations associated with adefovir dipivoxil of hepatitis B virus [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2015, 18(3): 312-316. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||